News for Altimmune, Inc. (3G0.F)

The COVID-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE has proved to be as effective in the real world as it was in clinical trials in...

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Shares of Altimmune Inc. undefined were down 4.8% in trading on Thursday after the company said it started enrolling participants in a Phase 1 clinical trial...

Shares of Altimmune Inc. undefined were down 4.1% in trading on Thursday, the day after the clinical-stage company said it had received regulatory approval...